

# List of COVID-19 vaccine authorizations

Save 14:08 by listening

0:00

1:10:42

⋮


National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.

Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi–GSK.<sup>[1]</sup> Seven others are under assessment by the WHO: Sputnik V, Sinopharm WIBP, Abdala, Zifivax, Corbevax, COVIRan Barekat, and SCB-2019.<sup>[2]</sup>

Of the 40 vaccines, 16 have a full or emergency authorization in only one country, 12 in ten or fewer countries, and 12 in more than ten countries.


Note that in some countries, vaccines may be authorized solely for travel purposes. They may not be approved for the general population. For example, the CoronaVac, Covishield, BBIBP-CorV and Covaxin vaccines are not part of Australia's national vaccination program; however, they are recognized for the purpose of travel to Australia.<sup>[3][4][5]</sup>

## Overview maps




RNA vaccines and DNA vaccines

- Pfizer–BioNTech (original)
- Pfizer–BioNTech (omicron)
- Moderna (original)
- Moderna (omicron)
- Others




Adenovirus vector vaccines

- Oxford–AstraZeneca
- Janssen
- Sputnik V
- Sputnik Light
- Convidecia
- iNOVACC



Inactivated virus vaccines

- Sinopharm BIBP
- CoronaVac
- Covaxin
- Valneva
- Sinopharm WIBP
- Others



Subunit vaccines

- Novavax
- Sanofi–GSK
- Abdala
- EpiVacCorona
- Zifivax
- Soberana 02
- Others

## Oxford–AstraZeneca

<input type="checkbox"/>	Full authorization
<input type="checkbox"/>	Emergency authorization